article thumbnail

STAT+: Oncologists more likely to provide low-value care after receiving pharma money, study finds

STAT

The other scenario involved treatments that were more expensive, but no more effective than alternatives, such as the Abraxane chemotherapy. The researchers examined Medicare beneficiaries who were diagnosed with cancer and received treatment from 2014 through 2019.

article thumbnail

‘What a gift to give’: For a woman struggling with infertility, a sister’s unexpected offer of surrogacy brings new hope

STAT

After the brain tumor diagnosis in 2016, Gatton would undergo two brain surgeries, radiation treatment, chemotherapy, followed by an embryo transfer that failed. But after all that, another embryo transfer had worked, and in fall 2019, Gatton was expecting. Read the rest…

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

STAT

But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion. STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure.

article thumbnail

STAT+: There’s a bill well-suited for drug shortage reforms, but Congress isn’t interested

STAT

Although not new, drug shortages are now a crisis, with an increasing number of reports about cancer doctors having to ration chemotherapies and other drugs. At the request of a large bipartisan group of lawmakers, a task force chaired by the Food and Drug Administration in 2019 reported on the root causes of drug shortages.

article thumbnail

USC-licensed startup NeOnc Technologies gets NASDAQ listing

Express Pharma

This is different from traditional chemotherapy which is usually given orally and intravenously. Researchers completed phase 1 clinical trials demonstrating safety and tolerance to NEO100 in 2019.

article thumbnail

Henlius claims win for PD-1 drug in small cell lung cancer

pharmaphorum

China’s Shanghai Henlius Biotech says its experimental PD-1 inhibitor serplulimab has extended survival when added to chemotherapy in a phase 3 trial as first-line therapy for extensive stage small cell lung cancer (ES-SCLC), setting up regulatory filings.

article thumbnail

Amneal Launches FYLNETRA (pegfilgrastim-pbbk) in the United States

Big Molecule Watch

According to the press release, FYLNETRA—Amneal’s third biosimilar launch in the United States since late last year—is used to treat neutropenia (low neutrophils, a type of white blood cell that fights infection) which is commonly experienced by patients undergoing chemotherapy.